Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,598.00
Bid: 12,596.00
Ask: 12,600.00
Change: 8.00 (0.06%)
Spread: 4.00 (0.032%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Japan's Suga urges citizens to have a quiet and distanced New Year

Fri, 25th Dec 2020 04:37

(Updates with reports on first cases of mutated coronavirus)

By Kiyoshi Takenaka and Tetsushi Kajimoto

TOKYO, Dec 25 (Reuters) - Japanese Prime Minister Yoshihide
Suga urged the nation on Friday to spend a quiet New Year period
without the usual social gatherings to prevent the spread of
COVID-19, which has been breaking infection records almost on a
daily basis.

Suga also announced a package of $2.6 billion for hospitals
treating COVID-19 patients which have come under strain due to
the rapid rise in cases across the northern island of Hokkaido
as well as large cities like Tokyo and Osaka.

"I want you to spend a quiet New Year," the premier told a
news conference in Tokyo with the government's leading
coronavirus expert Shigeru Omi.

"The infections aren't coming down and if we keep going like
this, we won't be able to avoid further spread of the virus."

The country confirmed its first cases of the new, faster-
spreading variant of the virus, in two citizens who had arrived
from the United Kingdom, domestic media reported late on Friday.

Japan has banned entry from United Kingdom, with the
exception of returning Japanese nationals and those with
residence permits.

Japan does not celebrate Christmas, but the New Year period
is an extended national holiday, with many people usually
travelling back to their hometowns and spending time with family
and friends.

Omi warned that it was critical that "all citizens move in
the same direction," to get a grip on the health crisis.

"If we don't bring infections down now, once they surge
again after the New Year period it won't be easy to change the
downward trend," he said. "It would take time, and would
probably be impossible to control over a period of weeks," he
said.

Omi said shared meals were a major cause of infections and
called on people to refrain from holding large gatherings and to
limit meals to four people one regularly ate with, or fewer.

While Japan has avoided the huge infection numbers seen in
other parts of the world, the number of new daily cases
surpassed 3,000 for the first time this month. Tokyo reported
884 infections on Friday, near Thursday's record 888.

HOSPITALS, VACCINES

Underscoring the strain on the hospitals, five national
groups of doctors and other medical workers made an emergency
request to Suga on Friday, asking for strong anti-pandemic
measures and support for the medical sector.

With hospitals equipped for treating COVID-19 filling up,
other hospitals are being forced to accept patients with the
disease, according to Tsuyoshi Masuda, president of the Japan
Federation of Democratic Medical Institutions.

"These small and medium-sized hospitals, which have been
supporting medical services in their respective regions, are
facing a crisis that is threatening their survival," Masuda told
reporters at a separate news conference on Friday.

He also warned that the risk of in-hospital infections was
high at institutions not specialized in dealing with infectious
diseases.

Japan, with a population of 126 million, has struck deals
to buy 290 million vaccine doses from Pfizer Inc,
AstraZeneca Plc and Moderna Inc, or enough for
145 million people.

A health ministry panel said that people aged 65 or older
should get priority for vaccination against COVID-19, as well as
frontline healthcare workers and people with underlying medical
conditions.

It specified chronic heart disease, chronic respiratory
disease and chronic kidney disease, among others, as underlying
conditions that should determine priority.

The panel's recommendations would mean 36 million elderly
people and 8.2 million people with medical conditions would be
the first to receive shots.
(Reporting by Kiyoshi Takenaka, Ju-min Park, Testsushi Kajimoto
and Antoni Slodkowski; Editing by Shri Navaratnam, Edmund
Klamann and William Mallard)

More News
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.